


Amendments to the Specification:

Please amend the specification at page 183 by replacing the paragraph describing preparation of Example A(153) with the following:

Example A(153): Preparation of compound (-)-2-(2-Chloro-4-{2-[2-cyclopentyl-5-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl}-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl)-ethyl}-phenyl)-2-methyl-propionitrile (-)-2-(4-{2-[2-Cyclopentyl-5-(5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl}-4-hydroxy-6-oxo-3,6-dihydro-2H-pyran-2-yl)-ethyl}-2-fluorophenyl)-2-methylpropionitrile



The title compound was prepared analogously to Example B(97), where (-)-2-[4-[2-(2-cyclopentyl-4,6-dioxotetrahydro-2H-pyran-2yl)ethyl]2-fluorophenyl]-2-methylpropanenitrile (from step 1 below) was substituted in place of 6-[2-(3-Chloro-5-ethyl-4-methoxy-phenyl)-ethyl]-6-cyclopentyl-dihydro-pyran-2,4-dione in that example. ^1H NMR (400MHz, DMSO- d_6): δ 1.25-1.57 (m, 8H), 1.72 (s, 6H), 2.11-2.17 (m, 2H), 2.50-2.56 (m, 8H), 2.63-2.65 (m, 2H), 2.78(d, J = 16 Hz, 1H), 3.71(d, J = 16 Hz, 1H), 3.84 (d, J = 16 Hz, 1H), 7.06 (s, 1H), 7.17-7.23 (m, 2H), 7.36-7.42 (m, 1H), 10.88 (s, 1H). Anal. Calcd. For $C_{30}H_{34}FN_5O_3$: 0.3 EtOAc: C, 65.15; H, 6.57; N, 12.55. Found: C, 66.86; H, 6.59; N, 12.21. MS(ESI): 532 ($M+H$) $^+$.